[1]郭荔,胡冬民,戴小华,等.糖尿病大鼠P-糖蛋白编码基因Abcb1 mRNA的表达及其对口服恩诺沙星药动学的影响[J].江苏农业学报,2017,(04):874-880.[doi:doi:10.3969/j.issn.1000-4440.2017.04.023]
　GUO Li,HU Dong-min,DAI Xiao-hua,et al.Abcb1 mRNA expression levels in different organs of diabetic rats and the effect on pharmacokinetics of oral enrofloxain[J].,2017,(04):874-880.[doi:doi:10.3969/j.issn.1000-4440.2017.04.023]
点击复制

糖尿病大鼠P-糖蛋白编码基因Abcb1 mRNA的表达及其对口服恩诺沙星药动学的影响()
分享到：

江苏农业学报[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2017年04期
页码:
874-880
栏目:
畜牧兽医·水产养殖
出版日期:
2017-08-30

文章信息/Info

Title:
Abcb1 mRNA expression levels in different organs of diabetic rats and the effect on pharmacokinetics of oral enrofloxain
作者:
郭荔; 胡冬民; 戴小华; 王丽平
（南京农业大学动物医学院，江苏南京210095）
Author(s):
GUO Li; HU Dong-min; DAI Xiao-hua; WANG Li-ping
(College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China)
关键词:
P-糖蛋白编码基因Abcb1; 大鼠; 糖尿病; 药动学参数
Keywords:
P-glycoprotein-encoding gene Abcb1; Sprague-Dawley rat; diabete; pharmacokinetic parameter
分类号:
S859.79
DOI:
doi:10.3969/j.issn.1000-4440.2017.04.023
文献标志码:
A
摘要:
试验旨在研究糖尿病大鼠肝脏、肾脏、空肠和回肠中P-糖蛋白编码基因Abcb1 mRNA的表达水平及其对口服恩诺沙星药动学的影响。通过链脲佐菌素（STZ）诱导建立清洁级雄性Sprague-Dawley (SD)大鼠的糖尿病模型，采用实时荧光定量法检测并比较2组（健康组和糖尿病组）大鼠不同器官中Abcb1 mRNA的表达差异，采用高效液相色谱法（HPLC）进一步测定糖尿病大鼠口服恩诺沙星的血药浓度。结果表明，糖尿病大鼠肝脏和回肠中Abcb1a mRNA的表达量显著高于健康组（P<005），肾脏和空肠中Abcb1a mRNA的表达量虽有波动，但差异不显著（P>005）。健康大鼠各器官中Abcb1b mRNA的表达水平与糖尿病大鼠相比未见显著差异（P>005）。口服恩诺沙星的药动学结果表明，糖尿病组大鼠血液中恩诺沙星的峰浓度、0～12 h的药-时曲线下面积和表观分布容积与健康组大鼠相比，均发生显著变化（P<001、P<005、P<005），其他药动学参数虽有变化，但差异不显著（P>005）。推测，糖尿病会导致大鼠体内Abcb1a mRNA的表达量发生变化，进一步导致口服药物在大鼠体内药动学过程发生变化。
Abstract:
To detect the Abcb1 mRNA expression in liver, kidney and intestines of diabetic rats and analyze its effect on the pharmacokinetics of oral enrofloxacin, the diabete model was firstly established. Real time RT-PCR method was used to detect the expression level of Abcb1 mRNA in different organs of diabetic and healthy rats. High performance liquid chromatography was applied to determine the concentration of enrofloxacin in diabetic rats. The results showed that the Abcb1a mRNA expression levels were increased significantly in the liver and ileum of diabetic rats（P<005）, but the differences were small in the jejunum and kidney （P>005）. The expression levels of Abcb1b showedin significant differences in the organs of both diabetic and healthy rats （P>005）. The pharmacokinetic parameters Cmax and AUC0-12 h significantly decreased (P<0.01, P<0.05), and V/F significantly increased （P<005） in diabetic rats. Other parameters did not show significant difference from those of healthy rats. Diabete might have led to the expression change of Abcb1a mRNA in rats, which could further cause the pharmacokinetics change of oral medications.

参考文献/References:

[1]JULIANO R L, LING V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1976, 455(1): 152-162.
[2]RONINSON I B. Molecular mechanism of multidrug resistance in tumor cells[J]. Clinical Physiology and Biochemistry, 1986, 5(3/4): 140-151.
[3]DEUCHARS K L, DU R P, NAIK M, et al. Expression of hamster P-glycoprotein and multidrug resistance in DNA-mediated transformants of mouse LTA cells[J]. Molecular and Cellular Biology, 1987, 7(2): 718-724.
[4]LING V. Multidrug resistance and P-glycoprotein expression[J]. Annals of the New York Academy of Sciences, 1987, 507(1): 7-8.
[5]董玲玲,郭荔,戴小华,等. P-糖蛋白在健康猪肝脏、肾脏和肠组织中的分布及其mRNA相对转录水平[J]. 畜牧兽医学报, 2013, 44(9):1454-1461.
[6]CHEN C, CHIN J E, UEDA K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells[J]. Cell, 1986, 47(3): 381-389.
[7]SAUNA Z E, KIM I W, AMBUDKAR S V. Genomics and the mechanism of P-glycoprotein (ABCB1)[J]. Journal of Bioenergetics and Biomembranes, 2007, 39(5/6): 481-487.
[8]郑婷婷,李敏,徐波,等. 基于P-gp功能的多药耐药逆转剂高内涵筛选方法的建立与应用[J]. 中国新药杂志, 2010(10):861-866.
[9]LIN J H, YAMAZAKI M. Role of P-glycoprotein in pharmacokinetics[J]. Clinical Pharmacokinetics, 2003, 42(1): 59-98.
[10]ZHANG Y, BENET L Z. The gut as a barrier to drug absorption[J]. Clinical Pharmacokinetics, 2001, 40(3): 159-168.
[11]BUNTING K D. ABC transporters as phenotypic markers and functional regulators of stem cells[J]. Stem Cells, 2002, 20(1): 11-20.
[12]EMERGING RISK FACTORS COLLABORATION. Diabetes mellitus, fasting glucose, and risk of cause-specific death[J]. N Engl J Med, 2011,364: 829-841.
[13]LIU H, LIU X, JIA L, et al. Insulin therapy restores impaired function and expression of P-glycoprotein in blood-brain barrier of experimental diabetes[J]. Biochemical Pharmacology, 2008, 75(8): 1649-1658.
[14]ZHANG Y, LI C, SUN X, et al. High glucose decreases expression and activity of p-glycoprotein in cultured human retinal pigment epithelium possibly through iNOS induction[J]. PLoS One, 2012, 7(2): e31631.
[15]温绍艳. 高糖和高胰岛素对MCF-7/ADR细胞P-糖蛋白表达和功能的影响[D]. 天津：天津医科大学, 2012.
[16]HARITOVA A M, SCHRICKX J A, FINK-GREMMELS J. Functional studies on the activity of efflux transporters in an ex vivo model with chicken splenocytes and evaluation of selected fluoroquinolones in this model[J]. Biochemical Pharmacology, 2007, 73(6): 752-759.
[17]ZHANG L, LU L, JIN S, et al. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats[J]. Acta Pharmacologica Sinica, 2011, 32(7): 956-966.
[18]董玲玲. P-糖蛋白在猪肝脏、肾脏和肠组织中的表达及对口服恩诺沙星药动学的影响[D]. 南京：南京农业大学, 2012.
[19]刘志浩,刘克辛. 肠道药物转运体及其研究方法[J]. 药学学报, 2011(4):370-376.
[21]HEMAUER S J, PATRIKEEVA S L, NANOVSKAYA T N, et al. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin[J]. American Journal of Obstetrics and Gynecology, 2010, 202(4): 383.e1-383.e7.
[22]LI C, CHOI D H, CHOI J S. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine[J]. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39(1): 99-108.
[23]CHU X Y, BLEASBY K, YABUT J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein[J]. Journal of Pharmacology and Experimental Therapeutics, 2007, 321(2): 673-683.
[24]BRAUD R, HUNEAULT L, BERNIER D, et al. Comparison of the selection of antimicrobial resistance in fecal Escherichia coli during enrofloxacin administration with a local drug delivery system or with intramuscular injections in a swine model[J]. Canadian Journal of Veterinary Research, 2008, 72(4): 311-319.
[25]SIKRI V, PAL D, JAIN R, et al. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux[J]. American Journal of Therapeutics, 2004, 11(6): 433-442.
[26]SHIMIZU A, MIYOSHI M, SUGIE M, et al. Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats[J]. European Journal of Pharmacology, 2004, 501(1): 151-159.
[27]BRILLAULT J, DE CASTRO W V, HARNOIS T, et al. P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model[J]. Antimicrobial Agents and Chemotherapy, 2009, 53(4): 1457-1462.
[28]DAUTREY S, FELICE K, PETIET A, et al. Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates[J]. British Journal of Pharmacology, 1999, 127(7): 1728-1734.
[29]苏利娅,董玲玲,王丽平. 球虫感染对蛋鸡肝脏和肠道mdr_1、mrp_2和bcrp mRNA表达水平的影响[J]. 南京农业大学学报, 2011, 34(6):95-99.
[30]KAMEYAMA N, ARISAWA S, UEYAMA J, et al. Increase in P-glycoprotein accompanied by activation of protein kinase Cα and NF-κB p65 in the livers of rats with streptozotocin-induced diabetes[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2008, 1782(5): 355-360.
[31]ZHANG L, LU L, JIN S, et al. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats[J]. Acta Pharmacologica Sinica, 2011, 32(7): 956-966.
[32]ANGER G J, MAGOMEDOVA L, PIQUETTE‐MILLER M. Impact of acute streptozotocin-induced diabetes on ABC transporter expression in rats[J]. Chemistry & Biodiversity, 2009, 6(11): 1943-1959.
[33]NAWA A, FUJITA-HAMABE W, TOKUYAMA S. Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model[J]. Life Sciences, 2011, 89(23): 834-838.
[34]NAWA A, FUJITA W, TOKUYAMA S. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions[J]. Life Sciences, 2010, 86(11): 402-409.

备注/Memo

备注/Memo:
收稿日期：2017-03-20 基金项目：国家重点研发计划（2016YFD0501309）；江苏省高校“青蓝工程”中青年学术带头人项目（2014） 作者简介：郭荔（1990-），女，内蒙古包头人，硕士研究生，主要从事兽医药理学与毒理学研究。（E-mail）1183820727@qq.com 通讯作者：王丽平，（E-mail）wlp71@163.com
更新日期/Last Update: 2017-09-01